Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions
We describe the cases of two patients treated with nirmatrelvir/ritonavir: a patient who had undergone kidney transplantation and another with a history of hematopoietic stem cell transplantation. Toxic concentrations of tacrolimus were induced in both. This case series highlights the risk associated with the concomitant administration of tacrolimus and nirmatrelvir/ritonavir.PMID:38698526 | DOI:10.1177/03000605241247705
Source: Cell Research - Category: Cytology Authors: Dan Shen Yinhua Gong Yulan Qian Jianguo Zhu Jie Gao Source Type: research
More News: Coronavirus | COVID-19 | Cytology | Food and Drug Administration (FDA) | Kidney Transplant | Kidney Transplantation | Norvir | Prograf | Stem Cell Therapy | Stem Cells | Tacrolimus | Toxicology | Transplants | Urology & Nephrology